- Home
- RVPH vs ENLV Comparison
RVPH vs ENLV Comparison
Compare RVPH & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- ENLV
- Stock Information
- Founded
- RVPH 2006
- ENLV 2005
- Country
- RVPH United States
- ENLV Israel
- Employees
- RVPH N/A
- ENLV N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- RVPH Health Care
- ENLV Health Care
- Exchange
- RVPH Nasdaq
- ENLV Nasdaq
- Market Cap
- RVPH 26.6M
- ENLV 23.7M
- IPO Year
- RVPH N/A
- ENLV 1995
- Fundamental
- Price
- RVPH $0.54
- ENLV $1.82
- Analyst Decision
- RVPH Strong Buy
- ENLV Strong Buy
- Analyst Count
- RVPH 5
- ENLV 2
- Target Price
- RVPH $8.00
- ENLV $10.00
- AVG Volume (30 Days)
- RVPH 2.8M
- ENLV 555.5K
- Earning Date
- RVPH 08-14-2025
- ENLV 08-29-2025
- Dividend Yield
- RVPH N/A
- ENLV N/A
- EPS Growth
- RVPH N/A
- ENLV N/A
- EPS
- RVPH N/A
- ENLV N/A
- Revenue
- RVPH N/A
- ENLV N/A
- Revenue This Year
- RVPH N/A
- ENLV N/A
- Revenue Next Year
- RVPH N/A
- ENLV N/A
- P/E Ratio
- RVPH N/A
- ENLV N/A
- Revenue Growth
- RVPH N/A
- ENLV N/A
- 52 Week Low
- RVPH $0.30
- ENLV $0.81
- 52 Week High
- RVPH $4.28
- ENLV $2.10
- Technical
- Relative Strength Index (RSI)
- RVPH 61.01
- ENLV 76.81
- Support Level
- RVPH $0.40
- ENLV $1.31
- Resistance Level
- RVPH $0.48
- ENLV $1.66
- Average True Range (ATR)
- RVPH 0.05
- ENLV 0.18
- MACD
- RVPH 0.01
- ENLV 0.04
- Stochastic Oscillator
- RVPH 58.53
- ENLV 65.85
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.